Neurovance Announces Agreement to Be Acquired by Otsuka Pharmaceutical

16:05 EST 2 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
--Acquisition Will Support Late-Stage Development of Neurovance’s Investigational New Drug Centanafadine for ADHD-- Neurovance, Inc. - a privately-held pharmaceutical company, working to develop a novel approach to help pa...

Other Sources for this Article

Initiate PR
Stephen Gendel, 310-776-7439


More From BioPortfolio on "Neurovance Announces Agreement to Be Acquired by Otsuka Pharmaceutical"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...